William Blair analyst Myles Minter has maintained their bullish stance on ARGX stock, giving a Buy rating on April 28.
Myles Minter has given his Buy rating due to a combination of factors including the strong performance of Argenx’s Vyvgart products, which exceeded both his and the consensus revenue estimates. Despite the stock’s premarket decline, Minter views this as an overreaction given the consistent quarterly growth of Vyvgart, even amidst seasonal challenges.
Additionally, the company’s net income aligned with expectations and surpassed consensus, indicating robust financial health. The ongoing expansion of Vyvgart’s indications, with recent approvals and upcoming regulatory decisions in key markets, further supports the positive outlook. Minter also highlights the promising pipeline developments, with significant study results anticipated in the coming years, which could drive future growth.
Minter covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Alnylam Pharma, and Arcturus Therapeutics. According to TipRanks, Minter has an average return of 5.0% and a 48.62% success rate on recommended stocks.
In another report released on April 28, Barclays also maintained a Buy rating on the stock with a €650.00 price target.